Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Treatment typically 4-6 weeks for acute injury, potentially longer for chronic conditions
In Vitro Effect of Short Peptides on Expression of Interleukin-2 Gene in Splenocytes
Principal Display Panel - Medication Box Rx only MEDICATION BOX (Box 1 of 2) NDC 62064-381-04 4 vials EGRIFTA WRTM (tesamorelin) for injection 11.6 mg/vial For Subcutaneous Use Single-patient-use vial Sterile lyophilized powder New Formulation, Dose, Mixing Instructions, and Storage One (1) mixed EGRIFTA WR vial provides daily doses for seven (7) days EGRIFTA WR and EGRIFTA SV are not substitutable
All amounts are total blend (about 50/50 per component)
Tissues were obtained through the National Disease Research Interchange (Philadelphia, PA) with approval from the University of Pittsburgh Committee for Oversight of Research and Clinical Training Involving Decedents (CORID)
Common sites include the upper arm (deltoid) and gluteal region, based on patient comfort and muscle mass
US$ 21.40
US$ 26.38
US$ 23.80
US$ 22.24
